checkAd

    Novavax, Inc.  493  0 Kommentare Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults - Seite 3

    Contact: Novavax, Inc.
     
    Barclay A. Phillips
    SVP, Chief Financial Officer and Treasurer
     
    Andrea N. Flynn, Ph.D.
    Senior Manager, Investor Relations

    Lesen Sie auch

     
    ir@novavax.com
    240-268-2000
     
    Russo Partners, LLC
     
    David Schull
    Todd Davenport, Ph.D.
     
    david.schull@russopartnersllc.com
    todd.davenport@russopartnersllc.com
    212-845-4271


    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novavax, Inc. via Globenewswire
    HUG#1973461
    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Novavax, Inc. Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults - Seite 3 Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced complete target enrollment of the pivotal Phase 3 clinical …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer